Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240537 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia (AML)
Multiple Myeloma (MM)
Myelodysplastic Syndrome (MDS)
Smoldering Multiple Myeloma (sMM)

Interventions

DRUG: Sargramostim
DRUG: BB-MPI-03
DRUG: Montanide

Sponsor

Benovus Bio, Inc.